StreetInsider.com News Articles

Form 144/A Adagene Inc. Filed by: GU CHUNFANG

Thu, 20 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957366.html

Form 144/A Adagene Inc. Filed by: GU CHUNFANG

Thu, 20 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957366.html

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York.

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Form 144 Adagene Inc. Filed by: GU CHUNFANG

Wed, 19 Aug 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260819/26948419.html

Form 144 Adagene Inc. Filed by: GU CHUNFANG

Wed, 19 Aug 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260819/26948419.html

Form 4 Adagene Inc. For: Aug 14 Filed by: DO CUONG V

Tue, 18 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945740.html

Form 4 Adagene Inc. For: Aug 14 Filed by: DO CUONG V

Tue, 18 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945740.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Zhu Li

Mon, 17 Aug 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26939335.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Zhu Li

Mon, 17 Aug 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26939335.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Cheung Andy Yiu Leung

Mon, 17 Aug 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26939333.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Cheung Andy Yiu Leung

Mon, 17 Aug 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26939333.html

Form 4 Adagene Inc. For: Aug 13 Filed by: DO CUONG V

Mon, 17 Aug 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26939331.html

Form 4 Adagene Inc. For: Aug 13 Filed by: DO CUONG V

Mon, 17 Aug 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26939331.html

Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932350.html

Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932350.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Grawunder Ulf

Fri, 14 Aug 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26927172.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Grawunder Ulf

Fri, 14 Aug 2026 11:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26927172.html

Form 6-K Adagene Inc. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908943.html

Form 6-K Adagene Inc. For: Jun 30

Wed, 12 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26908943.html

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Wed, 12 Aug 2026 07:30:00 -0400

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established

Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug’s potential as a backbone combination treatment for multiple tumor types across all lines of therapy

Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO agent through a clinical collaboration with Sanofi

Investigator-initiated

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Wed, 12 Aug 2026 07:30:00 -0400

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established

Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug’s potential as a backbone combination treatment for multiple tumor types across all lines of therapy

Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO agent through a clinical collaboration with Sanofi

Investigator-initiated

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Wed, 12 Aug 2026 07:30:00 -0400

Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established

Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug’s potential as a backbone combination treatment for multiple tumor types across all lines of therapy

Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO agent through a clinical collaboration with Sanofi

Investigator-initiated